Voyager Acquisition Corp. has entered into an amended agreement with Veraxa Biotech AG and Oliver Baumann, raising the total merger consideration to $1.35 billion from the previously agreed $1.3 billion. As part of the amendment, Veraxa has also agreed to waive a specific provision, allowing Voyager to propose changes to its corporate governing documents, specifically to remove a net tangible asset requirement. Additionally, the sponsor of Voyager Acquisition Corp. will forfeit 200,000 Class B Ordinary Shares and 400,000 SPAC Warrants at closing, with equivalent shares and warrants to be issued to Veraxa shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-000900), on February 03, 2026, and is solely responsible for the information contained therein.